2021
High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack RP, Saxon A, D’Onofrio G. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Network Open 2021, 4: e2117128. PMID: 34264326, PMCID: PMC8283555, DOI: 10.1001/jamanetworkopen.2021.17128.Peer-Reviewed Original ResearchConceptsOpioid use disorderEmergency departmentBuprenorphine inductionRespiratory depressionAdverse eventsUse disordersUntreated opioid use disorderSerious adverse eventsFurther prospective investigationLength of stayUrban emergency departmentSafety-net hospitalAdvanced practice practitionersElectronic health recordsUnique cliniciansSublingual buprenorphineBuprenorphine doseED visitsED encountersCase seriesED patientsED physiciansSupplemental oxygenMedian lengthUnique patientsA SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study
Edelman EJ, Dziura J, Deng Y, Bold KW, Murphy SM, Porter E, Sigel KM, Yager JE, Ledgerwood DM, Bernstein SL. A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study. Contemporary Clinical Trials 2021, 110: 106379. PMID: 33794354, PMCID: PMC8478961, DOI: 10.1016/j.cct.2021.106379.Peer-Reviewed Original ResearchConceptsTobacco use disorderNicotine replacement therapyUse disordersHIV clinicHybrid type 1 effectiveness-implementation designHIV viral load suppressionCD4 cell countViral load suppressionEffectiveness-implementation studyOptimal treatment approachPharmacist-delivered interventionSequential multiple assignmentHealth of personsImplementation science frameworkSecondary outcomesAntiretroviral treatmentPrimary outcomeClinical pharmacistsReplacement therapySmoking abstinenceTreatment approachesCell countHealth systemHIVContingency managementImplantable Cardioverter Defibrillator Lead Survival in Athletic Patients
Link MS, Sullivan RM, Olshansky B, Cannom D, Berul CI, Hauser RG, Heidbuchel H, Jordaens L, Krahn AD, Morgan J, Patton KK, Saarel EV, Wilkoff BL, Li F, Dziura J, Brandt C, Barth C, Lampert R. Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. Circulation Arrhythmia And Electrophysiology 2021, 14: e009344. PMID: 33724879, DOI: 10.1161/circep.120.009344.Peer-Reviewed Original Research
2020
Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients
Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, Garforth SJ, Herrera NG, Jangra RK, Morano NC, Orner E, Sy S, Chandran K, Dziura J, Almo SC, Ring A, Keller MJ, Herold KC, Herold BC. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine 2020, 12: eabd5487. PMID: 32958614, PMCID: PMC7658796, DOI: 10.1126/scitranslmed.abd5487.Peer-Reviewed Original ResearchConceptsImmune responsePediatric patientsAntibody titersAdult patientsSerum concentrationsT cellsSevere acute respiratory syndrome coronavirus 2IFN-γ serum concentrationsAcute respiratory syndrome coronavirus 2Robust T cell responsesSARS-CoV-2 infectionAntibody-dependent cellular phagocytosisRespiratory syndrome coronavirus 2Frequency of IFNMultisystem inflammatory syndromeT cell responsesCellular immune responsesSyndrome coronavirus 2Adaptive immune responsesAntiviral immune responseTumor necrosis factorMetropolitan hospital systemCoronavirus disease 2019COVID-19Age-dependent factorsIntegrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O’Connor P, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial. Addiction Science & Clinical Practice 2020, 15: 28. PMID: 32727618, PMCID: PMC7388231, DOI: 10.1186/s13722-020-00200-y.Peer-Reviewed Original ResearchConceptsRisk alcohol useAlcohol useAlcohol treatmentHealth of patientsEvidence-based strategiesWeek 24HIV outcomesRoutine careTelephone boosterPhysician managementEnhancement therapyHIVPWHPatientsTrialsTarget populationTreatmentAlcohol-related researchMulti-pronged approachOutcomesParticipantsInsufficient numberTherapyPopulationMethodsIn
2019
Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial. Journal Of Substance Use And Addiction Treatment 2019, 106: 97-106. PMID: 31540617, PMCID: PMC7244228, DOI: 10.1016/j.jsat.2019.08.007.Peer-Reviewed Original ResearchIntegrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The Lancet HIV 2019, 6: e509-e517. PMID: 31109915, PMCID: PMC7161741, DOI: 10.1016/s2352-3018(19)30076-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlcohol DrinkingAlcoholismCounselingFemaleHIV InfectionsHumansMaleMiddle AgedTreatment OutcomeUnited StatesYoung AdultConceptsAlcohol use disorderWeek 24Use disordersAlcohol treatmentAdverse eventsNumber of drinksTreatment medicationsPhysician managementAlcohol abuseMental Disorders-IV criteriaAlcohol-related careFormal alcohol treatmentKey exclusion criteriaTimeline followback methodMotivational enhancement therapyTreat populationHIV clinicHIV outcomesPrimary outcomeSpecialty referralsMean ageUS National InstitutesWeek 4Medical conditionsExclusion criteria
2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityCD3 ComplexCD8-Positive T-LymphocytesChildC-PeptideCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine releasePresentation, Clinical Profile, and Prognosis of Young Patients With Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): Results From the VIRGO Study
Safdar B, Spatz ES, Dreyer RP, Beltrame JF, Lichtman JH, Spertus JA, Reynolds HR, Geda M, Bueno H, Dziura JD, Krumholz HM, D'Onofrio G. Presentation, Clinical Profile, and Prognosis of Young Patients With Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): Results From the VIRGO Study. Journal Of The American Heart Association 2018, 7: e009174. PMID: 29954744, PMCID: PMC6064896, DOI: 10.1161/jaha.118.009174.Peer-Reviewed Original ResearchConceptsMI-CAD patientsNonobstructive coronary arteriesMI-CADYounger patientsClinical profileCoronary arteryMyocardial infarctionTraditional cardiac risk factorsAcute myocardial infarction patientsCardiac risk factorsGestational diabetes mellitusMyocardial infarction patientsTimes higher oddsMINOCA patientsSAQ qualityVIRGO StudyClinical characteristicsHypercoaguable stateDiabetes mellitusObstructive diseaseClinical outcomesInfarction patientsRisk factorsMINOCAPsychosocial statusNeurocognitive correlates of treatment response in children with Tourette's Disorder
Chang SW, McGuire JF, Walkup JT, Woods DW, Scahill L, Wilhelm S, Peterson AL, Dziura J, Piacentini J. Neurocognitive correlates of treatment response in children with Tourette's Disorder. Psychiatry Research 2018, 261: 464-472. PMID: 29407718, PMCID: PMC5809184, DOI: 10.1016/j.psychres.2017.12.066.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderBehavior therapyNeurocognitive functioningCo-occurring attention-deficit hyperactivity disorderPerformance speedTourette's disorderBrief neurocognitive batteryDeficit hyperactivity disorderBehavior therapy groupSmall negative associationNeurocognitive predictorsNeurocognitive correlatesCognitive functioningNeurocognitive batteryHabit learningPositive treatment responseHyperactivity disorderMotor inhibitionGroup differencesNeurocognitive statusFunctioningGreater baselineMemoryYouthNegative association
2017
Tobacco dependence treatment in the emergency department: A randomized trial using the Multiphase Optimization Strategy
Bernstein SL, Dziura J, Weiss J, Miller T, Vickerman KA, Grau LE, Pantalon MV, Abroms L, Collins LM, Toll B. Tobacco dependence treatment in the emergency department: A randomized trial using the Multiphase Optimization Strategy. Contemporary Clinical Trials 2017, 66: 1-8. PMID: 29287665, PMCID: PMC5851600, DOI: 10.1016/j.cct.2017.12.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultCost-Benefit AnalysisEmergency Service, HospitalFemaleHotlinesHumansMaleMiddle AgedMotivational InterviewingNicotine Chewing GumQualitative ResearchQuality-Adjusted Life YearsReferral and ConsultationSmoking CessationSmoking Cessation AgentsText MessagingTobacco Use Cessation DevicesTobacco Use DisorderTransdermal PatchTreatment OutcomeUnited StatesConceptsExhaled carbon monoxideHospital emergency departmentEmergency departmentMultiphase optimization strategyTobacco dependenceSubsequent confirmatory trialTobacco dependence interventionsNicotine replacement therapyTobacco dependence treatmentRecent clinical trialsLower socioeconomic groupsCost-effectiveness analysisPrimary endpointED patientsInitial treatmentStudy enrollmentTelephone quitlinesClinical efficacyPreventable causeReplacement therapyFuture trialsDependence treatmentTobacco abstinenceClinical trialsMulticomponent interventionModerators and predictors of response to behavior therapy for tics in Tourette syndrome
Sukhodolsky DG, Woods DW, Piacentini J, Wilhelm S, Peterson AL, Katsovich L, Dziura J, Walkup JT, Scahill L. Moderators and predictors of response to behavior therapy for tics in Tourette syndrome. Neurology 2017, 88: 1029-1036. PMID: 28202705, PMCID: PMC5384839, DOI: 10.1212/wnl.0000000000003710.Peer-Reviewed Original ResearchConceptsPredictors of responseChronic tic disorderTic reductionTic disordersPsychiatric disordersYale Global Tic Severity Scale-Total Tic ScoreTic severityTourette syndromeClinical Global Impressions-Improvement scoreCo-occurring psychiatric disordersAnxiety disordersSubgroup of patientsTotal tic scoreMain outcome measuresPredictors of outcomeBehavior therapyComprehensive Behavioral InterventionAttention-deficit/hyperactivity disorderPremonitory urge severityReduction of ticsCo-occurring attention-deficit/hyperactivity disorderGreater tic severityTIC characteristicsTic improvementClinical characteristicsRanolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial
Safdar B, D’Onofrio G, Dziura J, Russell RR, Johnson C, Sinusas AJ. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial. Clinical Therapeutics 2017, 39: 55-63. PMID: 28081848, PMCID: PMC10345862, DOI: 10.1016/j.clinthera.2016.12.002.Peer-Reviewed Original ResearchConceptsCoronary microvascular dysfunctionCoronary flow reserveCoronary artery diseaseChest painSymptomatic patientsArtery diseasePrimary outcomeEmergency departmentNonobstructive coronary artery diseaseRb-82 positron emission tomographyEffect of ranolazineRate-pressure productEmergency department patientsQTc-prolonging drugsRobust clinical trialsPositron emission tomographyHypertensive urgencyMicrovascular anginaMicrovascular dysfunctionUnderdiagnosed causeControlled TrialsDepartment patientsHeart failureAcute symptomsPressure product
2016
Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, O'Connor PG, Bedimo R, Gibert C, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Justice AC, Bryant KJ, Fiellin DA. Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients. Contemporary Clinical Trials 2016, 52: 80-90. PMID: 27876616, PMCID: PMC5253227, DOI: 10.1016/j.cct.2016.11.008.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useAlcohol use disorderHIV-positive patientsMotivational enhancement therapyAlcohol useWeek 12Risk drinkingWeek 4Effective evidence-based treatmentsInfectious disease clinicHIV-positive individualsModerate alcohol useEvidence-based treatmentsParticipants meeting criteriaImplementation of interventionsVACS IndexHIV careSecondary outcomesCare trialsDisease clinicHIV morbidityPrimary outcomeAlcohol pharmacotherapyInitial treatmentLiver diseaseRandomized controlled trials for degenerative lumbar spondylolisthesis: which patients benefit from lumbar fusion?
Ghogawala Z, Resnick DK, Glassman SD, Dziura J, Shaffrey CI, Mummaneni PV. Randomized controlled trials for degenerative lumbar spondylolisthesis: which patients benefit from lumbar fusion? Journal Of Neurosurgery Spine 2016, 26: 260-266. PMID: 27661562, DOI: 10.3171/2016.8.spine16716.Peer-Reviewed Original ResearchPsychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth
Taylor JH, Xu Y, Li F, Shaw M, Dziura J, Caprio S, Tamborlane WV, Nowicka P, Savoye M. Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth. Pediatric Obesity 2016, 12: 453-461. PMID: 27384496, PMCID: PMC5568975, DOI: 10.1111/ijpo.12165.Peer-Reviewed Original ResearchConceptsClinic careObese youthOutpatient clinic careAbnormal glucose toleranceObesity treatment outcomesObesity intervention programFamily functioningLifestyle interventionGlucose toleranceChildhood obesityLifestyle programTreatment outcomesPsychosocial predictorsIdentification of factorsIntervention programsIntervention outcomesOutcomesPoor family functioningTreatment effectsHigh anxietyBaselineCareMonthsInterventionLaminectomy plus Fusion versus Laminectomy Alone for Lumbar Spondylolisthesis
Ghogawala Z, Dziura J, Butler WE, Dai F, Terrin N, Magge SN, Coumans JV, Harrington JF, Amin-Hanjani S, Schwartz JS, Sonntag VK, Barker FG, Benzel EC. Laminectomy plus Fusion versus Laminectomy Alone for Lumbar Spondylolisthesis. New England Journal Of Medicine 2016, 374: 1424-1434. PMID: 27074067, DOI: 10.1056/nejmoa1508788.Peer-Reviewed Original ResearchConceptsPhysical component summary scoreDecompression-alone groupSF-36 physical component summary scoreFusion groupSummary scoresDecompressive laminectomySpinal stenosisGrade IOutcome measuresSpinal fusionOswestry Disability Index scoresSymptomatic lumbar spinal stenosisPhysical health-related qualityDegenerative grade IStable degenerative spondylolisthesisLonger hospital stayMore blood lossOswestry Disability IndexDisability Index scoresSecondary outcome measuresHealth-related qualityMedical Outcomes StudyPosterolateral instrumented fusionPrimary outcome measureLumbar spinal stenosis
2015
The influence of clopidogrel on ischemia diagnosed by myocardial perfusion stress testing
Jovin IS, Ebisu KA, Oprea AD, Brandt CA, Natale D, Finta LA, Dziura J, Wackers FJ. The influence of clopidogrel on ischemia diagnosed by myocardial perfusion stress testing. Journal Of Nuclear Cardiology 2015, 23: 773-779. PMID: 26338428, DOI: 10.1007/s12350-015-0268-3.Peer-Reviewed Original ResearchConceptsReversible perfusion defectsOdds ratioPerfusion defectsMyocardial perfusion stress testMyocardial perfusion stress testingStress testStress myocardial perfusion scansMyocardial single photon emissionAdenosine stress testInfluence of clopidogrelLikelihood of ischemiaMyocardial perfusion testingUse of clopidogrelCoronary vascular toneExercise stress testMyocardial perfusion scanMyocardial perfusion imagingSingle photon emissionAdenosine receptor antagonistDiagnosis of ischemiaPerfusion scanPerfusion testingVascular toneReceptor antagonistTomography scanExtended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal Of Psychiatry 2015, 172: 1197-1206. PMID: 26315981, DOI: 10.1176/appi.ajp.2015.15010055.Peer-Reviewed Original ResearchConceptsExtended-release guanfacineModal doseGuanfacine groupWeek 8Common adverse eventsAutism spectrum disorderWeeks of treatmentAttention deficit hyperactivity disorderDeficit hyperactivity disorderPlacebo groupAdverse eventsBlood pressurePlacebo subjectsClinical trialsSpectrum disorderPlaceboGuanfacineHyperactivityPulse rateHyperactivity disorderGroup differencesMotor planningWeeksBrief cognitive batteryDisorders
2014
The Effect of Modified Ultrafiltration on Angiopoietins in Pediatric Cardiothoracic Operations
Lang SM, Syed MA, Dziura J, Rocco E, Kirshbom P, Bhandari V, Giuliano JS. The Effect of Modified Ultrafiltration on Angiopoietins in Pediatric Cardiothoracic Operations. The Annals Of Thoracic Surgery 2014, 98: 1699-1704. PMID: 25258157, PMCID: PMC4253712, DOI: 10.1016/j.athoracsur.2014.06.053.Peer-Reviewed Original ResearchConceptsIntensive care unit admissionCare unit admissionModified ultrafiltrationUnit admissionCardiopulmonary bypassAngpt-2Interleukin-8Proinflammatory mediatorsClinical benefitAngpt-2 concentrationsInterleukin-10 levelsProspective cohort studySystemic inflammatory responseChildren 18 yearsEnzyme-linked immunosorbentCohort studyAntiinflammatory mediatorsInterleukin-10Inflammatory responseAngiopoietin-2Angpt-1Cardiothoracic operationsPatient's bloodAdmissionCytokine removal